Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 and RNK08954 in KRASG12D-positive Solid Tumors
NCT07441174Phase 2Recruiting
- Sponsor
- InxMed
- Start
- Feb 2026
- Primary completion
- Feb 2031
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib, RNK08954 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by InxMed. Started Feb 2026; status: recruiting.
02
Drugs
ifebemtinibRNK08954
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07441174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441174.